Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

NCT03767400 | Completed

• 1 other identifier: SCRIC18-OCT-01
• Study Type: observational
• Target: 99
• Locations: 1 country
• Sites: 1

Brief Summary

This single-center clinical study is being conducted over the course of 2 weeks to conduct an exploratory pilot study as a preliminary evaluation of D-OCT's ability to measure skin changes from aging. Assess structural differences between young and aged skin on the face. To identify the structural characteristics of atrophic acne scars relative to normal skin on the face. To explore characteristics of cellulite relative to normal skin on the thigh in young and aged skin.

Conditions

Skin Care

Outcome Measures

Primary Outcomes (4)

• VivoSight software measurements of Epidermal Thickness

  Epidermal thickness will be measured in microns.

  Day 1

• VivoSight software measurements of surface roughness

  Surface roughness measurements (Ra, Rq, Rz) will be measured in microns.

  Day 1

• VivoSight software measurements of redness

  Redness will be measured in percent

  Day 1

• VivoSight software measurements of attenuation coefficient

  Attenuation coefficient will be measured in AU (arbitrary unit)

  Day 1

Secondary Outcomes (15)

• Overall Photodamage Score at Day 1

  Day 1

• Overall Appearance of Fine Lines/Wrinkles Cheek Areas

  Day 1

• Post-study Dynamic Optical Coherence Tomography (D-OCT) Image Analysis of Epidermal Thickness

  Day 1

• Post-study D-OCT Image Analysis of Density and Attenuation Coefficient of Epidermis

  Day 1

• Post-study D-OCT Image Analysis of Density and Attenuation Coefficient of Superficial Dermis

  Day 1

Study Arms (3)

Group A - Young skin (18 - 30 years old)

Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.

Device: Skin Imaging; Other: Facial Cleanser

Group B - Aged skin (55 - 75 years old)

Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.

Device: Skin Imaging; Other: Facial Cleanser

Group C - Atrophic acne scars (18 - 75 years old)

Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.

Device: Skin Imaging; Other: Facial Cleanser

Interventions

Skin Imaging DEVICE

Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.

Group A - Young skin (18 - 30 years old); Group B - Aged skin (55 - 75 years old); Group C - Atrophic acne scars (18 - 75 years old)

Facial Cleanser OTHER

Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.

Also known as: SkinMedica® Facial Cleanser

Group A - Young skin (18 - 30 years old); Group B - Aged skin (55 - 75 years old); Group C - Atrophic acne scars (18 - 75 years old)

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Female Caucasian subjects with Fitzpatrick skin types I-III that meet one of the criteria listed; ages 18-30 years old without acne scars on the face with or without visible cellulite on posterior thigh, or ages 55-75 years old without acne scars on the face with or without visible cellulite on posterior thigh, or ages 18-75 years old with atrophic acne scars.

You may qualify if:

• Female Caucasian subjects with Fitzpatrick skin types I-III that meet one of the criteria listed below:
• Ages 18-30 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
• Ages 55-75 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
• Ages 18-75 years old with atrophic acne scars
• Subject has completed an appropriately administered informed consent process which includes signing the IRB approved consent form.
• Good general health and free of any disease state or physical condition (e.g. psoriasis, rosacea, scars, tattoos etc.) which, in the investigator's opinion, might impair evaluations of the test sites or expose the subject to an unacceptable risk by study participation.
• Willingness to remove all makeup on the day of the visit. Makeup may be applied after the study visit has been completed.
• Willingness to cleanse their face and remove all face makeup at each scheduled clinic visit. No other topical products should be applied to the face until the study visit has been completed.
• i. For cellulite subgroup, willingness to have thigh cleansed at each scheduled clinic visit.
• Willingness to have investigator exams, skin instrumentation measurements, and digital photos performed on the face and/or thigh (for cellulite subgroup).
• Women of childbearing potential must not be pregnant at the time of the study.

You may not qualify if:

• Has any condition that, in the opinion of the investigator, would make it unsafe for the subject to participate in the study or interfere with their clinical assessments (including conditions that require the concurrent use of anticoagulants, bleeding coagulopathies, photosensitivity diseases).
• Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, tattoos, or other skin conditions in the test areas that would interfere with the assessments of this study.
• Individuals who are pregnant.
• Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune.
• Individuals who have a pre-existing or dormant dermatologic condition (e.g. history of severe psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)
• Individuals who have routinely used any of the following topical products, prescription products, or had any of the listed treatments/procedures within the listed time frame prior to study entry or will use during study:
• Any product that the investigator deems that could affect the study objectives. These include products that address skin imperfections. This does not include a basic cleanser, moisturizer and sunscreen.(time frame 2 weeks)
• Chemical peel, microdermabrasion, dermaplaning, or microneedling (time frame 3 months)
• Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, Avage® or Differin® or other similar prescription drugs (time frame 3 months)
• Cosmetic injections (filler and/or toxins, i.e. Juvederm, Radiesse, Botox, etc.), non-ablative laser or fractional laser resurfacing (time frame 12 months)
• Accutane® or other oral retinoid, Ablative procedures (i.e. laser, chemical) (time frame 12 months)
• Individuals who have any planned surgeries or procedures during the study.
• Individuals who participated in a facial usage study within the last 30 days, or who are currently participating on another usage study.
• Individuals currently on or planning to participate on any type of research study at another facility or a doctor's office during this study.

Sponsors & Collaborators

• Allergan: lead

Study Sites (1)

Skinmedica Clinical Research and Innovation Center

Irvine, California, 92612, United States

Location

Study Officials

• Lisa Goberdhan

  Allergan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 5, 2018
• First Posted: December 6, 2018
• Study Start: December 7, 2018
• Primary Completion: May 31, 2019
• Study Completion: July 30, 2019
• Last Updated: October 31, 2019

Record last verified: 2019-10

Locations

US (1)